CD44 mAb engineered surface modified Poly(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles loaded with Aprepitant and Etoricoxib for simultaneous targeting of TNBC stem cells and cancer cells.
Kiet Group of Institutions,Ghaziabad, Uttar Pradesh, Dr. Chandrashekhar Venkaraddi Mangannavar, Institute of Public Health, Bengalore, Karnataka
Project Overview
TNBC, an aggressive subtype of breast cancer, lacks estrogen and progesterone receptors and the human epidermal growth factor receptor gene. Current therapeutic options focus on targeting TNBC cells, but conventional chemotherapeutic medications can spare TNBC stem cells, increasing the risk of tumor relapse. A successful strategy should target both TNBC cells and TNBCsCs simultaneously. The role of sP or tNK-1R and COX-2 enzyme in TNBC progression is well-established. The study hypothesizes that combining Aprepitant and Etoricoxib could introduce a new strategy in chemotherapy with superior anti-TNBC potential. Polymeric nanoparticles (PNPs) have been investigated as nano drug delivery systems due to their biodegradability, biocompatibility, and non-toxic properties. Engineering PNPs with TNBC-specific markers like CD44 can enhance the therapeutic efficacy of loaded drugs while minimizing toxic effects.
Source
Source
science and Engineering Research Board (sERB), DsT
Jss College of Pharmacy, Ooty, Tamil Nadu
Accessibility Controls